Cyclerion Therapeutics
CYCN
74 hedge funds and large institutions have $105M invested in Cyclerion Therapeutics in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 15 closing their positions.
113% more capital invested
Capital invested by funds: $49.1M → $105M (+$55.4M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 3.34% → 3.19% (-0.15%)
8% less funds holding
Funds holding: 80 → 74 (-6)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$255K |
| 2 |
D.E. Shaw & Co
New York
|
+$231K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$195K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$189K |
| 5 |
Renaissance Technologies
New York
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
AWH Capital
Dallas,
Texas
|
-$1.14M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$716K |
| 3 |
EP
Eversept Partners
New York
|
-$374K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$352K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$331K |
CYCN Hedge Fund Activity: Q2 2020 in Review
74 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q2 2020, worth a combined $105M — up 113% from $49.1M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CYCN and 9 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $255K. The largest seller was AWH Capital, cutting an estimated $1.14M.
- 74 institutional investors held Cyclerion Therapeutics (CYCN) as of Q2 2020, down from 80 in Q1 2020.
- Funds reported $105M of Cyclerion Therapeutics stock for Q2 2020, up 113% quarter-over-quarter.
- 9 funds opened new Cyclerion Therapeutics positions in Q2 2020 and 15 closed out, a net change of -6 holders.
- The largest Cyclerion Therapeutics buyer in Q2 2020 was Bridgeway Capital Management, an estimated $255K added.
- The largest Cyclerion Therapeutics seller in Q2 2020 was AWH Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2020.